COMy 2023 | Unmet needs in BPDCN and strategies to optimize care for patients
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses approaches to improve the scope of care for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Dr Cerchione explains that care for this patient group would benefit from a multidisciplinary effort and that institutions should be established to optimize diagnosis, prognosis, monitoring, and treatment. Dr Cerchione further describes the benefits of tagraxofusp, a CD123-directed targeted therapy, which has demonstrated tolerability and efficacy in patients with relapsed/refractory (R/R) BPDCN. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
